The treatment involves receiving dexamethasone through a vein within the first two days after the burn injury occurs. The medication will be given for up to 5 days while patients are in the hospital under close medical supervision. During this time, patients will also receive standard burn care and treatment.

Throughout the study, doctors will monitor patients for various health issues that can occur after severe burns, including breathing problems and kidney function. They will also track other complications such as infections and wound healing. Patients will be followed for up to 90 days to assess their recovery and overall health outcomes.

During the study, patients will receive the denovoSkin™ treatment, and their progress will be monitored over time. The study will look at how well the wounds close and how much scarring occurs after the treatment. The treatment involves implanting the skin graft onto the burn area, and the healing process will be observed at various intervals, such as 10 weeks, 3 months, and 6 months after the grafting. The study will also assess the quality of the skin and any potential infections at the grafted sites.

The trial aims to provide valuable information on whether denovoSkin™ can be a better option for patients with severe burns, offering improved healing and less scarring. This research could lead to advancements in burn treatment, providing new hope for those affected by serious burn injuries. The study is expected to continue until 2028, allowing for comprehensive data collection and analysis.

Participants in the study will be randomly assigned to receive either the antibiotics or a placebo, which is a substance with no active medication. The main goal is to see if these antibiotics can reduce the risk of infections, such as *postoperative sepsis* and *autograft lysis*, which is when the new skin graft does not take hold and requires another graft. The study will monitor patients for any signs of infection within seven days after their surgery.

Throughout the study, researchers will also observe other outcomes, such as the overall recovery and healing process, the length of hospital stay, and any potential colonization by *multiresistant bacteria*. The study is designed to provide valuable information on the best ways to prevent infections in burn patients undergoing this type of surgery, ultimately aiming to improve patient care and outcomes.

Participants in the study will receive the glucose solution, and their blood glucose levels will be measured at specific times to observe how the glucose is distributed in the body. This involves taking a blood sample, injecting a small amount of glucose, and then measuring the blood glucose level again after a short period. The study will also monitor other factors such as the volume of blood in the chest and the amount of water in the lungs, using a special device called PiCCO.

The study will last for four days, during which various measurements will be taken to gather information about the body’s response to the glucose treatment. The goal is to improve understanding of how glucose is distributed in patients with severe burns, which may help in managing their treatment more effectively in the future.

In this study, participants will receive either tranexamic acid or a placebo during their surgery. Tranexamic acid is given as a solution through an intravenous infusion, which means it is delivered directly into the bloodstream through a vein. Another solution, sodium chloride, which is commonly known as salt water, may also be used in the study. The study will monitor the volume of blood loss and the body’s process of breaking down blood clots, known as fibrinolysis, during the surgery.

The study aims to gather information on whether tranexamic acid can effectively reduce the need for blood transfusions and improve surgical outcomes for patients undergoing burn surgery. The research will also look at other factors such as the success of skin grafts, which are used to cover and heal the burn area, and any complications that may arise during or after the surgery. This information will help doctors understand the potential benefits of using tranexamic acid in burn surgeries and improve care for patients with burn injuries.

The purpose of the study is to understand how high doses of vitamin C might help improve the recovery of patients with severe burns. The study will compare the effects of vitamin C with a placebo, which is a substance with no active medication, to see if there is a difference in outcomes. The main focus is on whether vitamin C can help reduce the need for organ support, such as machines that help with breathing or medications that support heart function, and whether it can lower the risk of death within 28 days after the injury.

Participants in the study will receive vitamin C every six hours for a total of 96 hours. The study will monitor their progress over a period of 28 days to see how quickly they can be discharged from the hospital and how well they recover without needing additional organ support. The trial aims to provide valuable insights into the potential benefits of vitamin C for patients with severe burns, which could lead to improved treatment options in the future.

The purpose of the study is to evaluate how safe and effective this new skin graft is compared to the traditional method of using the child’s own skin, known as autologous split-thickness skin grafts (STSG). The study will involve children who have burns that require surgical treatment. During the study, the new skin graft will be applied to the burn area, and the healing process will be monitored over time. The study will look at how well the burn area heals and how the new skin graft compares to the traditional method in terms of covering the burn area and the quality of the healed skin.

Participants in the study will be observed for a period of time after the grafting procedure to assess the healing process. This includes checking the burn area at different intervals, such as four weeks and three months after the grafting, to see how well the skin has healed and to ensure there are no signs of infection. The study will also evaluate the quality of the scar one year after the procedure. The goal is to determine if the new skin graft can provide a better healing outcome for children with severe burns.

The purpose of the study is to evaluate the safety and effectiveness of the EHSG-KF treatment compared to the traditional method of using autologous split-thickness skin grafts (STSG). Participants in the study will receive both the new EHSG-KF treatment and the standard STSG treatment, allowing researchers to compare the results. The study will monitor how well the skin heals over time, looking at factors such as the area of skin covered by the graft and the quality of the scar that forms.

Throughout the study, participants will have regular check-ups to assess the healing process and any potential side effects. These check-ups will include evaluations of the skin’s appearance and elasticity, as well as monitoring for any signs of infection. The study aims to provide valuable information on whether the EHSG-KF treatment can offer a better alternative for patients with severe burns, potentially improving healing outcomes and reducing scarring.